TFV + LNG Vaginal Ring
Alternative Name: Tenofovir (TFV) and levonorgestrel (LNG) ring
Description: An ARV-based microbicide, tenofovir, and a progestin-only contraceptive, levonorgestrel, in a two-segment polyurethane vaginal ring.
Product Details
Duration: 90 days
Dose: 10-20 ug LNG (per day), 10 mg TFV (per day)
Active Pharmaceutical Ingredient (API):
Inactive material: polyurethane
Status Details
Status Details: - Phase 1 safety and PK/PD trial that began in late 2014 was completed.
- Phase 1 safety and PK/PD trial that began in late 2014 was completed.
Additional Information
References: Clark JT, et al. (2014) Engineering a Segmented Dual-Reservoir Polyurethane Intravaginal Ring for Simultaneous Prevention of HIV Transmission and Unwanted Pregnancy. PLoS ONE. 9(3): e88509.
Thurman AR, et al. (2018) Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women. PLoS One. 13(6); e0199778.
Press Release: www.conrad.org/news-pressreleases-93.html
CONRAD website: www.conrad.org/prevention-trials.html
Clinicaltrials.gov Identified NCT02235662
Clark JT, et al. (2014) Engineering a Segmented Dual-Reservoir Polyurethane Intravaginal Ring for Simultaneous Prevention of HIV Transmission and Unwanted Pregnancy. PLoS ONE. 9(3): e88509.
Thurman AR, et al. (2018) Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women. PLoS One. 13(6); e0199778.
Press Release: www.conrad.org/news-pressreleases-93.html
CONRAD website: www.conrad.org/prevention-trials.html
Clinicaltrials.gov Identified NCT02235662